Controversy still exists regarding
axis in man. We studied the effects of the administration of placebo, pyridostigmine (PD; 120 mg, orally), and the combination of PD and pirenzepine (PZP; 100 mg, orally) on ACTH, cortisol, and GH secretion at 0730 and 2230 h in seven normal males. PD induced a clear decrease in ACTH levels at both times of the day compared to treatment with placebo, producing higher suppression in the nocturnal period (34.4 2 5.8% us. 21.8 t 10.7%). The combination PD and PZP prevented the inhibitory action of PD on ACTH secretion in the morning, but not in the evening, when ACTH values showed a decrease similar to that seen after giving PD alone (38.1 ? 5.6% us. 34.4 2 5.80/u, respectively).
Cortisol values declined only when the association PD plus PZP was given in the evening.
GH levels had a significant increase after PD administration in the morning (4.1 t 1.2 ng/mL) and in the evening (10.2 2 1.6 ng/mL), confirming that cholinergic stimulation was taking place, whereas the addition of PZP to PD induced a significant attenuation of these responses.
It and evening values (53.6 -C 3%). The administration of PD plus PZP in the morning prevented the inhibitory effect of PD on ACTH secretion, resulting in a secretory pattern identical to that found when subjects were pretreated with placebo ( Fig. 1) . Thus, ACTH total AUC values were reduced by only 6 t 1.3% with respect to those after placebo treatment.
In contrast, pretreatment with both drugs in the evening did not modify the decreasing effect on ACTH levels induced by exclusive I'D administration. In fact, total AUC values (Table 1) and integrated ACTH levels corresponding to partial time intervals were similar under both sets of conditions (Fig. 1) . The percent reduction in ACTH total AUC with respect to that during the placebo test was identical to that calculated after exclusive I'D treatment (38.1 & 5.6%). However, the ACTH area corresponding to the initial interval after I'D plus PZP was slightly lower than that measured after exclusive administration of I'D (6.7 -t 1.1 DS. 8.1 -C 1.4 pmol/L*30 min; P = NS; Fig. 1 ). Consequently, the combined treatment with I'D and PZP induced an amplification of circadian ACTH variation (62.6 i 5.5%; P < 0.05 us. placebo).
Cortisol
Morning basal cortisol levels after placebo treatment were maximal at 0800 h (516.9 i 33.9 nmol/L) and declined progressively throughout the sampling period (nadir, 1015 h; 264.1 t 26 nmol/L; Fig. 2 response in the morning as well as the evening (mean GH peak, 4.1 -C 1.2 and 10.2 -C 1.6 ng/mL, respectively).
Thus, GH AUC values after I'D treatment
were superior to those found after placebo treatment at both times of the day (Table l), confirming that cholinergic stimulation was taking place. The percent GH stimulation over basal values after PD treatment was higher in the morning (1574 + 214% vs. 70.9 5 15%). The addition of PZP to PD led to a marked reduction of the GH response to I'D in the morning (GH peak, 0.73 t-0.4 vs. 4.1 -C 1.2 ng/mL; P < 0.01) as well as in the evening (3.66 t 2.34 'us. 10.2 t 1.6 ng/mL; P < 0.05). Estimations of GH total AUC values also suggested that cholinergic GH stimulation was significantly attenuated when both drugs were given (Table 1) (8), who did not find any change in ACTH levels after the administration of I'D to normal subjects in the morning. One possible explanation is that stressful effects due to I'D administration could lead to HPA axis activation in some individuals, thus contributing to mask the real cholinergic effect on morning ACTH secretion just when the inhibitory effect of I'D on ACTH secretion seems to be weaker. The stimulation of cortisol and P-endorphin secretion induced by low doses of physostigmine in old men could be due to disturbances in the cholinergic system related to aging (10). The impairment of GH responses to the cholinergic agonist exhibited by the same individuals supports that hypothesis. Our study demonstrates that the ACTH inhibition induced by PD administration in the morning is completely abolished by the addition of PZP, suggesting that the reduction in ACTH concentrations observed at that time of day requires the participation of Ml muscarinic receptors. Stimulation of GH secretion by I'D and its inhibition by concurrent PZP treatment support the view that cholinergic tone manipulation was, in fact, taking place as expected. Finally, the inhibitory effect of I'D on ACTH secretion cannot be ascribed to stress, a condition that promotes ACTH and cortisol release. There is a genuine possibility that doses of I'D superior to those given in this study have a different effect on ACTH secretion. However, this is unlikely because administration of doses higher than 120 mg has been reported to cause similar GH release (16). In addition, high doses of I'D may produce significant side-effects and stress system activation, leading to HPA axis stimulation by noncholinergic mechanisms.
Our data agree with those reported by Evans et al. (17), who showed that iv administration of atropine in the morning increased the ACTH and P-endorphin responses to insulin-induced hypoglycemia in normal subjects, attributing to cholinergic muscarinic receptors an inhibitory influence on stimulated ACTH secretion. Unfortunately, no information was available on the effect of muscarinic receptor blockade on spontaneous HPA activity in this study.
To date, no studies have been conducted to investigate the effect of cholinergic stimulation on nocturnal HPA activity. Our data show that the inhibitory effect of I'D on ACTH secretion is also operative at night, despite the fact that absolute concentrations and pulsatility of ACTH secretion differ from those observed during the morning period. ACTH inhibition during the initial and middle phases of the sampling period was greater in the evening as was the overall suppression of ACTH levels compared to those found in the morning, suggesting that corticotroph sensitivity to the inhibitory effect of PD is higher during the nocturnal period. However, the addition of PZP does not reverse the PDinduced reduction of ACTH secretion, suggesting that Ml muscarinic receptors are not involved in the nocturnal effect of I'D on ACTH secretion. Thus, in contrast to results obtained in morning experiments, the association of I'D and PZP led to a decrease in ACTH levels comparable to that seen after PD alone. These results are consistent with the participation of cholinergic receptors different from those of the Ml type in the nocturnal effect of PD on ACTH levels, raising the possibility that modulation of ACTH secretion by the cholinergic system involves a different type of receptor depending on the time of the day.
PD administration induced a substantial GH response during both study periods as a consequence of somatostatin inhibition (18), thus corroborating an effective stimulation of cholinergic tone. Relative GH increase after pretreatment with PD in the morning was greater than that found in the evening, suggesting a low somatostatinergic tone during the nocturnal period, as previously proposed (19). This circadian variation in the GH response to PD is not paralleled by that of ACTH, which suggests that the mechanisms mediating GH stimulation after cholinergic agonist administration may be different from those involved in ACTH suppression, as has been suggested in elderly people (10).
Regarding the mechanisms by which PD inhibits ACTH secretion, a suprapituitary site of action should be considered, as there is no proof of the existence of cholinergic receptors on corticotroph cells, and according to this, addition of the cholinergic agonist arecoline to dispersed anterior pituitary cells in culture does not have any effect on ACTH secretion (5). The fact that PZP, due to its hydrophilic properties, does not penetrate the blood-brain barrier to a great extent (20) points to the median eminence as the most likely site of action for this drug to antagonize the effects of PD on ACTH release. However, effects on other hypothalamic structures leading to changes in CRH or AVP secretion cannot be ruled out, as experimental evidence suggests that cholinergic pathways have a significant influence on the synthesis of both peptides (21, 22) .
Interestingly, cortisol levels remained unchanged despite the fact that ACTH concentrations were reduced after pretreatment with PD. This suggests that the sensitivity of adrenal glands to small changes in ACTH levels is not enough to induce significant variations in cortisol concentrations. Alternatively, the sampling period might be too short to detect a reduction of cortisol concentrations that may occur later. Furthermore, a direct adrenal effect of cholinergic drugs cannot be ruled out. In this context, a stimulatory effect of acetylcholine infusions on adrenal cortisol output in hypophysectomized animals has been described (23). Thus, PD administration may counteract the effects of ACTH reduction by promoting direct adrenal cortisol release. These results are in agreement with other studies (B-10) that failed to find any cortisol variation when giving PD to normal subjects in the morning, and with that of Evans et al. (17) , who observed no changes in hypoglycemia-stimulated cortisol levels after atropine administration to normal individuals despite achieving a significant rise in ACTH concentrations. The addition of PZP induced a significant decrease in cortisol values in the initial phase of the nocturnal test, just when maximum ACTH suppression was attained. A superior reduction of ACTH levels in the early part of the experiment or a direct effect of PZP on adrenal cortisol release represent possible mechanisms to explain the different cortisol patterns seen after the administration of PD and PZP. It seems that both factors, a decrease in ACTH levels and simultaneous administration of PZP, are required to induce a significant reduction in cortisol levels. Taken together, these data indicate that estimation of cortisol levels is not a reliable index to assess the effects of cholinergic manipulation on corticotroph cell function.
When assessing the relationship between diurnal and nocturnal HPA activities, it becomes evident that the percent variation in ACTH or cortisol observed after placebo administration remained constant after pretreatment with PD. However, the differences seen in the cortisol and ACTH responses to combined PD and PZP treatment at both times of the day give support to the possibility of a modulatory influence of cholinergic tone on the circadian rhythm of the HPA axis.
In summary, this study reveals that, in contrast to experimental animals, cholinergic activation by PD inhibits ACTH secretion in man, suggesting the involvement of a different type of cholinergic receptors depending on the time of day at which the test is carried out. This functional relationship between the cholinergic system and the HPA axis provides further insight into the regulation of HPA function and opens new perspectives in the pathophysiology of behavior disorders and stress conditions.
